Collins Benjamin, Smith Chelsey, Anderson Michael, Garrana Sherief, Allen Pamela, Vasan Nilesh R
J Okla State Med Assoc. 2015 Jan;108(1):8-12.
Non-melanoma skin cancers (NMSC) are especially prone to develop in the immunosuppressed population. There is insufficient data regarding outcomes and mortality for immunosuppressed individuals with NMSC of the head and neck.
What are the mortality indicators for immunosuppressed subjects with head and neck NMSC?
This retrospective chart review analyzes all immunosuppressed patients diagnosed with any stage NMSC at an academic tertiary care institution from 2006-2011.
Thirty four patients are analyzed. Odds of mortality is significantly increased for patients who required multiple surgeries (adjusted odds ratio (aOR)=23.98, 95%CI=(1.411, 407.599)) and those who were immunocompromised secondary to leukemia (aOR=28.27, 95%CI=(1.838, 434.73)).
Patients with leukemia and NMSC may have an increased risk of mortality compared to other immunocompromised patients with NMSC. Immunocompromised patients with NMSC may have a worse prognosis if multiple surgeries are required. Knowledge of mortality indicators may aid in the management of these immunocompromised patients.
非黑色素瘤皮肤癌（NMSC）在免疫抑制人群中尤其容易发生。关于头颈部NMSC免疫抑制个体的预后和死亡率的数据不足。
头颈部NMSC免疫抑制受试者的死亡指标是什么？
这项回顾性病历审查分析了2006年至2011年在一家学术三级医疗机构被诊断为任何阶段NMSC的所有免疫抑制患者。
分析了34例患者。需要多次手术的患者（调整后的优势比（aOR）=23.98，95%置信区间=（1.411，407.599））以及继发于白血病的免疫功能低下患者（aOR=28.27，95%置信区间=（1.838，434.73））的死亡几率显著增加。
与其他患有NMSC的免疫抑制患者相比，患有白血病和NMSC的患者可能有更高的死亡风险。如果需要多次手术，患有NMSC的免疫抑制患者的预后可能更差。了解死亡指标可能有助于对这些免疫抑制患者的管理。
